Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking
Abstract Purpose The purpose of this study was to assess the feasibility, efficacy and toxicity of fiducial marker implantation and tracking in CyberKnife® stereotactic radiation therapy (SBRT) applied to extracranial locations. Materials and method This is a retrospective, single-centre, observatio...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Radiation Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13014-019-1373-2 |
id |
doaj-1501ebcf18a54dda8921a491ebfa56db |
---|---|
record_format |
Article |
spelling |
doaj-1501ebcf18a54dda8921a491ebfa56db2020-11-25T03:31:03ZengBMCRadiation Oncology1748-717X2019-09-011411810.1186/s13014-019-1373-2Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial trackingNathaniel Scher0Marc Bollet1Gauthier Bouilhol2Remi Tannouri3Imane Khemiri4Aurelie Vouillaume5Noura Sellami6Rie Von Eyben7Jean-Michel Vannetzel8Ilan Darmon9Luc Rotenberg10Hanah Lamallem11Olivier Bauduceau12Denis Foster13Alain Toledano14Hartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteDepartment of Statistical Analysis, Radiation Oncology, Stanford University School of MedicineHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteHartmann Radiotherapy InstituteAbstract Purpose The purpose of this study was to assess the feasibility, efficacy and toxicity of fiducial marker implantation and tracking in CyberKnife® stereotactic radiation therapy (SBRT) applied to extracranial locations. Materials and method This is a retrospective, single-centre, observational study to collect the data of all patients treated by stereotactic radiation therapy with fiducial marker tracking at extracranial locations, conducted between June 2014 and November 2017. Information regarding the implantation procedure, the types of toxicity related to marker implantation and the number of markers implanted/tracked during treatment were collected. Complication rates were evaluated using the CTCAE v4 [Common Terminology Criteria for Adverse Events] scale. The technical success rate was based on the ability to optimally track the tumor throughout all treatment fractions. Results Out of 2505 patients treated by stereotactic radiation therapy, 25% received treatment with fiducial marker tracking. The total number of implantation procedures was 616 and 1543 fiducial markers were implanted. The implantation-related complication rate was 3%, with 16 Grade 1 events and 4 Grade 2 events. The number of treated patients and the number of implanted markers has gradually increased since the technique was first implemented. The median treatment time was 27 min (range 10–76). 1295 fiducials were effectively tracked throughout all treatment fractions, corresponding to a technical success rate of 84%. The difference between the number of fiducials implanted and those tracked during treatment decreased significantly as the site’s experience increased. Conclusion Fiducial marker implantation and tracking is feasible, well-tolerated, and technically effective technique in SBRT for extracranial tumors.http://link.springer.com/article/10.1186/s13014-019-1373-2Stereotactic body radiation therapyImage guided radiation therapyFiducial marker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nathaniel Scher Marc Bollet Gauthier Bouilhol Remi Tannouri Imane Khemiri Aurelie Vouillaume Noura Sellami Rie Von Eyben Jean-Michel Vannetzel Ilan Darmon Luc Rotenberg Hanah Lamallem Olivier Bauduceau Denis Foster Alain Toledano |
spellingShingle |
Nathaniel Scher Marc Bollet Gauthier Bouilhol Remi Tannouri Imane Khemiri Aurelie Vouillaume Noura Sellami Rie Von Eyben Jean-Michel Vannetzel Ilan Darmon Luc Rotenberg Hanah Lamallem Olivier Bauduceau Denis Foster Alain Toledano Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking Radiation Oncology Stereotactic body radiation therapy Image guided radiation therapy Fiducial marker |
author_facet |
Nathaniel Scher Marc Bollet Gauthier Bouilhol Remi Tannouri Imane Khemiri Aurelie Vouillaume Noura Sellami Rie Von Eyben Jean-Michel Vannetzel Ilan Darmon Luc Rotenberg Hanah Lamallem Olivier Bauduceau Denis Foster Alain Toledano |
author_sort |
Nathaniel Scher |
title |
Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking |
title_short |
Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking |
title_full |
Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking |
title_fullStr |
Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking |
title_full_unstemmed |
Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking |
title_sort |
safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking |
publisher |
BMC |
series |
Radiation Oncology |
issn |
1748-717X |
publishDate |
2019-09-01 |
description |
Abstract Purpose The purpose of this study was to assess the feasibility, efficacy and toxicity of fiducial marker implantation and tracking in CyberKnife® stereotactic radiation therapy (SBRT) applied to extracranial locations. Materials and method This is a retrospective, single-centre, observational study to collect the data of all patients treated by stereotactic radiation therapy with fiducial marker tracking at extracranial locations, conducted between June 2014 and November 2017. Information regarding the implantation procedure, the types of toxicity related to marker implantation and the number of markers implanted/tracked during treatment were collected. Complication rates were evaluated using the CTCAE v4 [Common Terminology Criteria for Adverse Events] scale. The technical success rate was based on the ability to optimally track the tumor throughout all treatment fractions. Results Out of 2505 patients treated by stereotactic radiation therapy, 25% received treatment with fiducial marker tracking. The total number of implantation procedures was 616 and 1543 fiducial markers were implanted. The implantation-related complication rate was 3%, with 16 Grade 1 events and 4 Grade 2 events. The number of treated patients and the number of implanted markers has gradually increased since the technique was first implemented. The median treatment time was 27 min (range 10–76). 1295 fiducials were effectively tracked throughout all treatment fractions, corresponding to a technical success rate of 84%. The difference between the number of fiducials implanted and those tracked during treatment decreased significantly as the site’s experience increased. Conclusion Fiducial marker implantation and tracking is feasible, well-tolerated, and technically effective technique in SBRT for extracranial tumors. |
topic |
Stereotactic body radiation therapy Image guided radiation therapy Fiducial marker |
url |
http://link.springer.com/article/10.1186/s13014-019-1373-2 |
work_keys_str_mv |
AT nathanielscher safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT marcbollet safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT gauthierbouilhol safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT remitannouri safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT imanekhemiri safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT aurelievouillaume safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT nourasellami safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT rievoneyben safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT jeanmichelvannetzel safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT ilandarmon safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT lucrotenberg safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT hanahlamallem safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT olivierbauduceau safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT denisfoster safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking AT alaintoledano safetyandefficacyoffiducialmarkerimplantationforroboticstereotacticbodyradiationtherapywithfiducialtracking |
_version_ |
1724573954888171520 |